DUBLIN--(BUSINESS WIRE)--The "Male Hypogonadism - Pipeline Review, H2 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.
Male Hypogonadism - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Male Hypogonadism (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Male Hypogonadism (Male Health) pipeline guide also reviews key players involved in therapeutic development for Male Hypogonadism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Unknown stages are 3, 2, 4, 5, 2, 4 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.
Male Hypogonadism (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered:
- Introduction
- Report Coverage
- Male Hypogonadism - Overview
- Male Hypogonadism - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Male Hypogonadism - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Male Hypogonadism - Companies Involved in Therapeutics Development
- Antares Pharma Inc
- Clarus Therapeutics Inc
- Diurnal Group Plc
- EndoCeutics Inc
- Ferring International Center SA
- Lipocine Inc
- M et P Pharma AG
- Medlab Clinical Ltd
- Merck & Co Inc
- Mereo Biopharma Group Plc
- Repros Therapeutics Inc
- TesoRx Pharma LLC
- Viramal Ltd
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/nnbkm5/male_hypogonadism?w=4
